Positive Phase 1 data shows potential of CK-0045 to improve cardiometabolic risk factorsCytoki Pharma has revealed positive data from a Phase 1 study evaluating the safety, tolerability and pharmacokinetics of CK-0045, its...
Phenomix Sciences and InformedDNA enter partnership to advance genetics-driven obesity care13 hours ago
Banded-RYGB associated with statistically significant increases in percentage excess weight loss at five years15 hours ago